SCHEMBL20239281

SCHEMBL20239281

CN1CCN(c2nc(C#N)cc(Oc3ccc(CS(N)(=O)=O)cc3)n2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.61
KDM4E B2RXH2 3/20 0.51
HPGD P15428 1/20 0.51
PTBP1 P26599 1/20 0.51
ALDH1A1 P00352 3/20 0.46
LMNA P02545 1/20 0.42
HTR6 P50406 2/20 0.41
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
ATM Q13315 1/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
UBE2N P61088 1/20 0.39
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239202 0.88 LMNA (0.54) DGAT2KDM4EHPGDPTBP1ALDH1A1
SCHEMBL20239355 0.87 DGAT2 (0.48) DGAT2KDM4EHPGDPTBP1ALDH1A1
SCHEMBL20239273 0.84 DGAT2 (0.70) DGAT2ALDH1A1HTR6KMT2ASMN1; SMN2
SCHEMBL20252424 0.84 DGAT2 (0.46) DGAT2LMNASMN1; SMN2CA12CA1
SCHEMBL16738664 0.79 PDE2A (0.41) DGAT2KDM4EHPGDALDH1A1LMNA
SCHEMBL18249758 0.77 DGAT2 (0.41) DGAT2KDM4EHPGDALDH1A1LMNA
SCHEMBL20239199 0.76 DGAT2 (1.00) DGAT2HTR6GAAHRH4CA12
SCHEMBL20239187 0.76 LMNA (0.41) DGAT2KDM4EALDH1A1LMNAKMT2A
SCHEMBL20239178 0.72 DGAT2 (0.55) DGAT2ALDH1A1LMNAKMT2ASMN1; SMN2
SCHEMBL18249749 0.71 SMN1; SMN2 (0.38) DGAT2KDM4EHPGDPTBP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107635975-B DGAT2 inhibitors 伊莱利利公司 2020-07-24 CN disclosed
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885KDM4E 4070/4885HPGD 2550/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885KDM4E 3891/4885HPGD 2139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.